

UNITED STATE DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

	IO
FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.

09/236,995 01/26/99 MAHAJAN

5718-34

000826 ALSTON & BIRD LLP P O DRAWER 34009 CHARLOTTE NC 28234-4009

FILING DATE

APPLICATION NO.

HM12/0925 EXAMINER

ZAGHMOUT, O

ART UNIT PAPER NUMBER

DATE MAILED:

09/25/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



L

ES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED	APPLICANT	ATTORNEY DOCKET NO.
09/236,995				
г		١		EXAMINER
			Ousama M-Faiz	Zaghmout
			ART UNIT	PAPER NUMBER
			1638	6
1		J	DATE MAILE) :

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicants must comply with sequence rules as stated in the MPEP (37 CFR 1.821 Nucleotide and/or amino acid sequence disclosures in patent applications). Please see also 2422.01: Definitions of Nucleotide and/or Amino Acids for Purpose of Sequence Rules.

Any inquiry concerning this communication should be directed to Examiner Ousama M-Faiz Zaghmout, Art Unit [1638], whose telephone number is [703-308-94381.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Application No.: 09/236,995

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

		his application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's ttention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
		2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
		3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	X	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
		5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
		6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
		7. Other:
	Аp	plicant Must Provide:
/	X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
		An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
'	X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
	Foi	r questions regarding compliance to these requirements, please contact:
		Rules Interpretation, call (703) 308-4216
		r CRF Submission Help, call (703) 308-4212 tentIn Software Program Support (SIRA)
		Technical Assistance703-287-0200
		To Purchase PatentIn Software703-306-2600